Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will support its growth, per Piper Sandler.
Get this delivered to your inbox, and more info about our products and services.
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
The investment bank upgraded the pharma stock to overweight from equal weight.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
RBC's $22 price target implies an upside of 74% for shares of Biohaven.
The bank initiated the clinical-stage biotechnology firm at a buy rating.
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
